Pharmaceuticals News

ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose...

Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly...

SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly...

WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious...

PharmAla Biotech provides a corporate update relating to its investment banking partner, Canaccord Genuity LLC, and its IP.

Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of care regimens1This immunotherapy doublet...

National Institute for Health and Care Excellence guidance supports NHS funding and wider patient access to life-saving organ transplantation technology

COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the second quarter and first half of 2026 and released...

KØBENHAVN, Danmark, 21. august 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag sine delårsresultater og den forretningsmæssige udvikling for andet kvartal og første halvår af 2026 samt...